US2014199288A1PendingUtilityA1

Pharmaceutical compositions containing botulinum neurotoxin

Assignee: ALLERGAN INCPriority: Feb 8, 2000Filed: Mar 17, 2014Published: Jul 17, 2014

Est. expiryFeb 8, 2020(expired)· nominal 20-yr term from priority

B65D 85/70A61K 8/65A61K 8/64A61K 47/183A61K 8/732A61K 9/19A61K 8/66A61K 38/39A61K 47/42A61K 47/36A61Q 19/08C07K 14/33A61K 38/164A61K 8/9728A61K 9/0019A61K 8/02A61K 39/08A61K 31/715A61K 8/44A61K 38/4893A61K 2800/91A61K 8/99A61K 47/22

PatentIndex Score

Cited by

References

Claims

Abstract

This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000 D.

Claims

exact text as granted — not AI-modified

1 . A pharmaceutical composition, comprising: (a) a botulinum toxin, and (b) a recombinant human serum albumin, wherein the pharmaceutical composition is in a lyophilized or vacuum-dried condition for reconstitution. 
     
     
         2 . (canceled) 
     
     
         3 . The pharmaceutical composition of  claim 1 , further comprising an acetyltryptophanate or salts or derivatives thereof. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the recombinant human serum albumin was expressed in yeast cells. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the botulinum toxin is botulinum toxin type A.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.